Diversity, Inclusion and Meaningful Participation in Clinical Trials

One of a series of live panels recorded at the WCG Patient Advocacy Forums in Washington D.C. in October, 2019.

The persistent lack of diversity in clinical trials means many therapies are never tested on the very patients for whom they are intended. What can we do to make sure that study populations reflect patient populations, and that data is being generated that will be as generalizable as possible?

Lori Abrams, senior director of patient advocacy at WCG took on this topic with Dorelia Rivera, patient advocate and mother of a daughter with an ultra-rare disease, Kimberly Richardson, patient advocate and six-year survivor of a rare ovarian cancer and Jonca Bull, former assistant FDA commissioner.

Click the slides above, or download the PDF to read insights on this topic from patients, patient advocates, and industry leaders.